AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)
Zacks Investment Research | Sep 30, 2021 01:21AM ET
AstraZeneca (NASDAQ:AZN)’s industry .
Image Source: Zacks Investment Research
AstraZeneca had acquired joint development and commercialization rights to Enhertu from Japan’s Daiichi Sankyo in April 2019. Sales of Enhertu in the United States are recognized by Daiichi Sankyo while AstraZeneca records its share of profit from the sales of the drug in the United States as collaboration revenues. Enhertu was approved for its second indication, HER2+, metastatic gastric cancer in January 2021 while it is also being evaluated for other cancer types.
At ESMO, AstraZeneca also presented three-year data from the CASPIAN phase III study in its PD-L1 inhibitor, Imfinzi. The data showed that Imfinzi plus chemotherapy tripled patient survival at three years in first-line extensive-stage small cell lung cancer
Please note that Imfinzi is already approved for the first-line treatment of extensive-stage small cell lung cancer in combination with standard-of-care platinum chemotherapy in several countries based on OS data from the CASPIAN phase III study. The latest results from the CAPIAN study showed that Imfinzi plus chemotherapy resulted in a 29% reduction in the risk of death versus chemotherapy alone after a median follow up of more than three years. The data also showed that an estimated 17.6% of patients in the Imfinzi plus chemotherapy arm were alive at three years, versus 5.8% of those in the chemotherapy alone arm. Median OS was 12.9 months in the Imfinzi plus chemotherapy arm against 10.5 for the chemotherapy alone arm.
Imfinzi is also approved to treat unresectable, stage III non-small-cell lung cancer (NSCLC).
Enhertu and Imfinzi are part of AstraZeneca’s flourishing oncology portfolio. Other key oncology drugs in AstraZeneca’s portfolio are Tagrisso and Lynparza. AstraZeneca markets Lynparza in partnership with MerckREGN , which has a Zacks Rank #1 (Strong Buy).
Regeneron’s shares have gained 32.7% this year so far. Its earnings estimates for 2021 and 2022 have risen from $50.00 per share to $58.89.
(We are reissuing this article to correct a mistake. The original article, issued on September 21, 2021, should no longer be relied upon.)
Get The News You Want
Zacks’ Top Picks to Cash in on Artificial Intelligence
This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.
See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.